*Импакт фактор за 2018 г. по данным РИНЦ
Журнал входит в Перечень рецензируемых научных изданий ВАК.
Читайте в новом номере
Ко мне обратился пациент К., 59 лет, интеллигентный, культурный человек, работающий в Ростовском техническом университете.
Данная статья опубликована при финансовой поддержке компании GlaxoSmithKline
Литература
1. Lepor H. Phase III multicenter placebo–controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998 Jun;51(6)892–900.
2. Mary Lee Tamsulosin for the Treatment of Benign Prostatic Hypertrophy Ann Pharmacotherapy. 2000 34 (2)188–199
3. J. Curtis Nickel et al. The beneficial effect of alfuzosin 10 mg once daily in ‘real–life’ practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation BJU Int. 97(6) 1242–1246
4. Claus G. Roehrborn et al. Efficacy and safety of a dual inhibitorof 5–alpha–reductase types 1 and 2, (dutasteride) in men with benign prostatic hyperplasia Urology 2002 60: 434–441,
5. J. Mc Connell et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among menwith benign prostatic hyperplasia The New England Journal of Medicine 1998; 338 (9)557–563
6. J. Mc Connell et al. The Long–Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia The New England Journal of Medicine 2003 349 № 25, 2387–2398.
7. Claus G. Roehrborn еt al. The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4–Year Results from the CombAT Study Eur Urol 2010 (57)123–131.